2026-05-06_库莫西利一线乳腺癌获批

• 来源: 公告/披露原始TXT转换
• 日期: 2026-05-06
• 涉及公司: 中国生物制药
• 涉及主题: 2026-05-06 库莫西利一线乳腺癌获批
• 一句话摘要: 由同目录 TXT/HTML 原始文件转换生成的 Markdown 主阅读版，原始文件保留作备份；具体内容以正文为准。
• 来源文件: sources/filings/中国生物制药/2026-05-06_库莫西利一线乳腺癌获批.txt
• 转换日期: 2026-05-12
• 类型: TXT/HTML 转 Markdown 主阅读版
• 说明: 本文件由同目录 TXT/HTML 轻量转换生成；原始文件保留作备份。

---

1
ҁ
፠༈ഃʫ
ዄ΂Оப΂f
ʮ̡
ၣ१jwww.sbpgroup.com
΅ᇜ໮j1177
Іᗴʮѓ
୽Глᇭᚾ ˜CDK2/4/6ᐕԪ໗ᐖอቇᏐसᐏҭɪ̹
ʮ̡ € ˜͉ʮ̡᙮ʮ̡୕၈ ˜͉ණྠ ™  ໨ԫึ € ˜໨ԫึбd͉ණ
ʮ̡ € ˜͍ɽ˂౹࢕1୽Глᇭᚾ
˜CDK2/4/6ؚ®္ຖ၍ଣ҅(NMPA)ݯ
ዧ९ա᜗ (HR)Ϊɿա᜗ 2 (HER2)٫
ୋ2 ධቇᏐसf
׵CULMINATE-2ࡈ࠯CDK2/4/6ҵՓኒᑌΥ
׵HR+/HER2-׵2025໕
ኪึ(ESMO)ࠅLBA)ϣʮ̺ [1]j
• ͛πಂ(mPFS)މNR ͊༺Ց
vs. 20.2Э44% €HR=0.56d p=0.0004ᝈᇠ༆ଟ(ORR)ܵ
ග(DOR)ࣩ
ٙPFSᐏूf

2
• ᗫʔԄԫ΁ (TRAEs)މ1-2၍ଣi ≥3ߤ
೯͛ଟස 20.3%ᐕ୞˟ˢԷස 3.5%̙છ˲
၍ଣf
໕ᆯfՉʕdHR+/HER2-ԭ
ٙ65%-70% [2] f ʕ਷ᑗґ໕ᆯኪึ(CSCO)€2025‘ ഃ ᛆ
પᑥCDK4/6މHR+/HER2-ࣩ[3,4] f್Ͼdʥ
Ϟ30%-40%ᖹ [5]f
ٙCDK2/4/6ҵՓኒdஷཀ੶ʷ࿁CDK2 ձCDK4Э࿁
CDK6͟CDK2ၾ
̻ፅ [6]f
ٙ࢝HR+/HER2-Ԫ໗ᐖቇᏐसdʊ
׵2025ϋ 12˜ᐏ੻NMPA஗ॶɝ  CSCO€2026
׵HR+/HER2-ٙIII ಂᑗґ༊᜕͍ίආ
ع
ᐕ፯኿f
Ը๕j
[1] Erwei song, et al. Culmerciclib plus fulvestrant as first-line treatment for HR+/HER2- advanced breast cancer cancer: A
phase 3 trial (CULMINATE-2), ESMO 2025 LBA25.
[2] ڡ.Бषኪᒈැʿԣછ઼ͪj2018–2022జѓ‘ ༆ᛘ[J]. ʕ਷౷̮ਿ
ᓾၾᑗґᕏႦd2024, 31(07): 796-802.
[3] National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guideline). Breast
Cancer, version 5. 2023[EB/OL]. [2024-01-12].
[4] ึdᇜഹ. یܸ2025[M]. ٟو.
[5] Abu-Khalaf, M.M., Alex Hodge, K., Hatzis, C. et al. AKT/mTOR signaling modulates resistance to endocrine therapy
and CDK4/6 inhibition in metastatic breast cancers. npj Precis. Onc. 7, 18 (2023).

3
[6] Xu Z, Liu Y, Song B, et al. Discovery and preclinical evaluations of TQB3616, a novel CDK4-biased inhibitor.
Bioorganic & Medicinal Chemistry Letters 2024; 107.
໨ԫึն
ʮ̡
ࢩ
ᑽՉᆗ
ಥdɚཧɚʬϋʞ˜ʬ˚
ᆗ
ɾ
ɻeੵኁ˃΋͛ʿҽ਷ಊᔼ͛f

关联页面

• 公司页：中国生物制药(01177.HK)